olaparib | New Drug Approvals
Olaparib - Wikipedia, la enciclopedia libre
PharmaWiki - Olaparib
HemOnc.org | A Hematology Oncology Wiki
Olaparib: Cos'è, A Cosa Serve, Quando si Assume
Targeting dePARylation selectively suppresses DNA repair–defective and PARP inhibitor–resistant malignancies | Science Advances
763113-22-0 Olaparib - Watson International Ltd
PARP inhibitors: Synthetic lethality in the clinic | Science
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
olaparib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
令癌莎- Wikiwand
Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
Tankyrase inhibitors as antitumor agents: a patent update (2013 – 2020)
Olaparib - Wikipedia
BRCA Support Liverpool
Olaparib - Wikipedia
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. - Abstract - Europe PMC
COH34 is a potent and cell-active PARG inhibitor. (A) Predicted... | Download Scientific Diagram
Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian ca
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. - Abstract - Europe PMC
